Want to see SNGX full AI Analyst Report?
SNGX Stock Chart & Stats
$0.37
<$0.01(0.76%)
At close: 4:00 PM EDT
$0.37
<$0.01(0.76%)
Day’s Range― - ―
52-Week Range$0.28 - $6.23
Previous CloseN/A
Volume151.23K
Average Volume (3M)538.52K
Market Cap
$8.16M
Enterprise Value$6.30
Total Cash (Recent Filing)$6.03M
Total Debt (Recent Filing)$330.66K
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Aug 07, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding21,765,478
10 Day Avg. Volume362,298
30 Day Avg. Volume538,521
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.50Price Target Upside305.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Non-dilutive Government FundingStable access to government grants and cost-reimbursement contracts provides a durable financing channel for R&D in biodefense and rare-disease programs. This reduces near-term reliance on product sales, supports ongoing development cadence, and can enable multi-quarter program continuity while seeking approvals or partners.
Material Reduction In LeverageA much lower debt load materially reduces interest and covenant risk, improving financial flexibility for a small clinical-stage biotech. Lower leverage preserves options to fund trials or pursue strategic alternatives over months and reduces the risk that financing needs are exacerbated by fixed debt service obligations.
Expanded At-the-market (ATM) Financing CapacityAn enlarged ATM facility provides a repeatable, opportunistic equity funding tool to cover operating needs without negotiating discrete financing deals. Over the medium term this improves liquidity planning and allows management to support pipeline activities or M&A flexibility, albeit with dilution trade-offs.
Bears Say
Zero Revenue And Persistent Cash BurnNo commercial revenue combined with a roughly $10M annual cash burn creates a structural funding requirement. Sustained losses force ongoing capital raises or dependence on government contracts; repeated dilution or constrained runways can limit ability to execute multi-program development and negotiate favorable partnerships.
Phase 3 HyBryte Program TerminatedTerminating a late-stage program removes a potential near-term value-creating asset and eliminates an avenue to regulatory approval or partnering. This reduces pipeline optionality, extends the timeline to potential revenues, and may force strategic shifts that increase execution risk and reliance on remaining, earlier-stage assets.
Nasdaq Minimum Bid Non-compliance RiskA Nasdaq non-compliance notice creates meaningful operational and financing risk: potential delisting would reduce liquidity, hinder capital raising, and complicate partner or investor relations. Even if remediated, management attention and resources over months must be diverted to regain compliance or seek alternatives.
Soligenix News
SNGX FAQ
What was Soligenix Inc’s price range in the past 12 months?
Soligenix Inc lowest stock price was $0.28 and its highest was $6.23 in the past 12 months.
What is Soligenix Inc’s market cap?
Soligenix Inc’s market cap is $8.16M.
When is Soligenix Inc’s upcoming earnings report date?
Soligenix Inc’s upcoming earnings report date is Aug 07, 2026 which is in 6 days.
How were Soligenix Inc’s earnings last quarter?
Soligenix Inc released its earnings results on May 08, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Soligenix Inc overvalued?
According to Wall Street analysts Soligenix Inc’s price is currently Undervalued.
Does Soligenix Inc pay dividends?
Soligenix Inc does not currently pay dividends.
What is Soligenix Inc’s EPS estimate?
Soligenix Inc’s EPS estimate is -0.16.
How many shares outstanding does Soligenix Inc have?
Soligenix Inc has 21,765,478 shares outstanding.
What happened to Soligenix Inc’s price movement after its last earnings report?
Soligenix Inc reported an EPS of -$0.28 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.87%.
Which hedge fund is a major shareholder of Soligenix Inc?
Currently, no hedge funds are holding shares in SNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Soligenix Inc
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
SNGX Stock 12 Month Forecast
Average Price Target
$1.50
▲(305.41% Upside)
Technical Analysis
Ownership Overview
0.15% Insiders
0.62% Mutual Funds
<0.01% Other Institutional Investors
98.86% Public Companies and
Individual Investors